IP Library Granted Patent US 11,672,790
Granted Patent B2
US 11,672,790 · App. 16/676,030 · Granted Jun 13, 2023

Methods of managing conditioned fear with neurokinin receptor antagonists

Inventors: Kerry J. Ressler (Atlanta, GA); Raul Andreo Gali (Atlanta, GA)
Assignee: Emory University
A61K31/4545A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,672,790
App. No.
16/676,030
Granted
Jun 13, 2023
Kind
B2
Abstract

This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.

Claims (7)

1. A method of reducing the risk of developing symptoms of PTSD in a subject that is at high-risk of developing PTSD, wherein said method comprises:

administering an effective amount of osanetant to the subject within 24 hours of experiencing a trauma that is a high-risk event for the development of PTSD;

wherein a high-risk event is selected from a group consisting of: a sexual assault and combat; and

wherein the administration begins prior to the subject developing a symptom of PTSD and after experiencing the high-risk event.

2. The method of claim 1 , wherein the subject is a human and the effective amount is a daily dose of about 25 mg per day.

3. The method of claim 1 , wherein the effective amount is a daily dose of between 10 and 40 mg per day.

4. The method of claim 1 , wherein osanetant or a salt thereof is administered at the time of or within an hour of psychotherapy, cognitive behavioral therapy, exposure therapy, cognitive restructuring, or stress inoculation training.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: ZEVRA THERAPEUTICS INC. (AS SUCCESSOR IN INTEREST TO NANTAHALA CAPITAL MANAGEMENT, LLC, AS SUCCESSOR IN INTEREST TO SWK FUNDING LLC)
To: ACER THERAPEUTICS INC.
Reel/Frame 067020/0036 →
SECURITY INTEREST Recorded Jul 6, 2023
From: SWK FUNDING LLC; ACER THERAPEUTICS INC
To: NANTAHALA CAPITAL MANAGEMENT, LLC
Reel/Frame 064167/0828 →
SECURITY INTEREST Recorded Mar 11, 2022
From: ACER THERAPEUTICS INC.
To: SWK FUNDING LLC
Reel/Frame 059237/0638 →